Dyne Therapeutics, Inc. DYN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $392.78M+14.4% | $398.33M+41.6% | $384.71M+48.9% | $380.29M+72.2% | $343.32M+57.7% | ||
| $78.31M+45.6% | $69.85M+11.8% | $64.46M+15.1% | $60.64M+20.8% | $53.79M+11.8% | ||
| $471.09M+18.6% | $468.18M+36.1% | $449.16M+42.8% | $440.93M+62.7% | $397.1M+49.4% | ||
| $471.09M+18.6% | $468.18M+36.1% | $449.16M+42.8% | $440.93M+62.7% | $397.1M+49.4% | ||
| -$471.09M-18.7% | -$468.18M-36.2% | -$449.16M-42.9% | -$440.84M-62.6% | -$397.01M-49.3% | ||
| $10.39M— | $6.19M— | $3M— | $94K— | $0— | ||
| $31.52M+1.6% | $29.86M+10.9% | $29.79M+41.3% | $30.59M+119% | $31.02M+239% | ||
| $19.38M-35.3% | $21.97M-17.0% | $25.36M+27.1% | $28.05M+108% | $29.97M+254% | ||
| -$451.71M-23.0% | -$446.21M-40.6% | -$423.8M-43.9% | -$412.89M-60.3% | -$367.13M-42.6% | ||
| -$3.19+11.1% | -$3.51-4.8% | -$3.66-2.8% | -$3.86-7.5% | -$3.59+9.6% | ||
| -$3.19+11.1% | -$3.51-4.8% | -$3.66-2.8% | -$3.86-7.5% | -$3.59+9.6% | ||
| -$452.09M-23.3% | -$445.75M-40.4% | -$423.78M-44.1% | -$412.39M-60.0% | -$366.76M-42.5% | ||
| $31.52M+1.6% | $29.86M+10.9% | $29.79M+41.3% | $30.59M+119% | $31.02M+239% | ||
| -$357K— | $490K— | —— | —— | —— | ||
| $19.38M-35.3% | $21.97M-17.0% | $25.36M+27.1% | $28.05M+108% | $29.97M+254% | ||
| -$1.74M-65.9% | -$1.7M-274% | -$1.43M-26.9% | -$2.45M-378% | -$1.05M-51.2% | ||
| 549.2M+38.2% | 494M+34.0% | 459.7M+37.6% | 418.8M+42.3% | 397.4M+51.9% | ||
| 549.2M+38.2% | 494M+34.0% | 459.7M+37.6% | 418.8M+42.3% | 397.4M+51.9% | ||
| -$471.09M-18.7% | -$468.18M-36.2% | -$449.16M-42.9% | -$440.84M-62.6% | -$397.01M-49.3% | ||
| -$469.02M-18.7% | -$466.16M-36.2% | -$447.21M-43.0% | -$438.99M-62.9% | -$395.26M-49.6% | ||
| -$469.02M-18.7% | -$466.16M-36.2% | -$447.21M-43.0% | -$438.99M-62.9% | -$395.26M-49.6% | ||
| -$471.09M-18.7% | -$468.18M-36.2% | -$449.16M-42.9% | -$440.84M-62.6% | -$397.01M-49.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dyne Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.